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two different quarters between 01/01/2006 and 12/31/2008. A patient was consid-
ered to have had new onset T2DM in 2008 under one of three conditions; firstly,
he/she had not received a diagnosis of T2DM in 2006 and 2007; secondly, had not
received oral anti-diabetics in 2006/2007; and thirdly, had received either one in-
patient or two outpatient T2DM diagnosis in 2008. RESULTS: In our sample, a total
of 254,523 patients had T2DM. The prevalence of T2DMwas 4.69 % (women: 3.26%;
men: 6.03%). The average age of these T2DM patients was 64.8 years, and 66.4%
weremale. The incidence of T2DM in our sample was 4.889 cases per 1,000 person-
years in men and 2.863 cases in 1,000 person-years in women. T2DM prevalence/
incidence strongly depended on gender and age. Whereas the T2DM prevalence in
both men and women was below 0.9% in all age groups 40 years, it increased up
to 25.17% (men)/24.34% (women) in the second-highest age group, 85-90 years.
CONCLUSIONS:A comparison of the distribution of AF prevalence/incidence in our
population with that in already published studies shows that our figures are com-
paratively high. Obviously, in a large industrial nation such as Germany, care pro-
vision structures are going to be challenged by the requirement to treatmore T2DM
patients in the future.
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OBJECTIVES: Previous research has shown patients with diabetes have a higher
risk of death following pneumonia. This study examined the impact of diabetes
diagnosis on in-hospital mortality and length of stay in the inpatient setting.
METHODS: MedAssets health system data (October 2010 to September 2011) were
analyzed for adult inpatients with a principle diagnosis of community-acquired
pneumonia. Cohorts of patientswith andwithout type 2-diabeteswerematched on
age and sex using a propensity score and Greedy matching algorithm. In-hospital
mortality and length of stay were compared between cohorts using multivariate
logistic and negative binomial regression models, respectively, controlling for age,
gender, admission source and type, ventilator use, Deyo-Charlson comorbidity
score, hospital bed size, region, and teaching status. RESULTS: Of 282,474 patients
with pneumonia, approximately 19% had diabetes. Matching resulted in 34,999
patients in each cohort with a mean age of 69 and proportionately more females
than males (51.8% vs. 47.9%). Diabetic patients had higher Deyo-Charlson scores
(3.14 vs. 2.49, p 0.0001) and higher rates of ventilator use (14.1% vs. 10.3%, p
0.0001). Patients diagnosed with diabetes were 26% less likely to die during hospi-
talization (OR  0.74, CI  0.68-0.80). Diabetic patients had a 2% longer length of
stay (IRR  1.02, CI  1.01-1.04). CONCLUSIONS: After controlling for other vari-
ables, patients with type-2 diabetes had a lower risk of in-hospital mortality and
longer length of stay when hospitalized for pneumonia compared to patients with-
out diabetes. Glucose levels at the time of admission and history of diagnosis may
explain some of the association, while care of diabetic patients and residual ben-
efits of other treatments may have reduced the risk of in-inpatient mortality. Fur-
ther studies should assess post-hospitalization outcomes.
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OBJECTIVES: To determine which factors were associated with sustained poor or
good glycemic control over three years. METHODS: This retrospective study of
enrollees in a large health plan in Hawaii with diabeteswas restricted to thosewith
poor control at baseline (HbA1c9% in the year 2006), who had HbA1c values for
four years (2006-2009, n2970). Separate multivariable logistic regressions exam-
ined factors related to poor (HbA1c9%) or good (HbA1c7%) control over three
years. Independent variables included age, gender, island of residence, type of
coverage, comorbid conditions, diabetes duration, and number of medications.
RESULTS: Relative to patientswith diabetes duration of a year or less, patientswith
diabetes for8 yearswere significantly less likely to sustain good control [OR0.13,
95%CI(0.09, 0.21)], as were patients with diabetes for 6-7 years [OR0.23,
95%CI(0.13, 0.39)], and 4-5 years [OR0.17, 95%CI(0.09, 0.31)]. Compared to patients
in HMO, patients in PPO or Medicare cost contract were significantly more likely to
have good control. Factors significantly related to poor control were age, diabetes
duration, morbidity level, and number of medications. Relative to patients aged
50-64, younger patients were significantlymore likely to have poor control [age35
OR1.98, 95%CI(1.25, 3.14); age 35-49 OR 1.27, 95%CI(1.03, 1.57)] and older patients
were significantly less likely [age 65-79 OR0.75, 95%CI(0.57, 0.98); age 80
OR0.63, 95%CI (0.41, 0.97)]. Longer diabetes duration and higher morbidity in-
creased the risk of poor control, while patients taking 15medications decreased
the risk. CONCLUSIONS: As diabetes duration strongly predicted poor control, pri-
mary prevention to decrease early onset of diabetes might be a cost-effective
means to reduce the number of patients with poor control. Our findings that
younger patients with diabetes are most likely to have poor control suggest that
interventions need to be targeted to this population.
DIABETES/ENDOCRINE DISORDERS – Cost Studies
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OBJECTIVES: Diabetes mellitus is a syndrome characterized by chronic hypergly-
cemia with absolute or relative deficiencies of insulin and/or in its action. The
National Health System (SUS), through the pharmaceutical assistancemust ensure
medications and supplies needed for the monitoring of capillary blood glucose of
diabetic patients, defined byministerial decree. The aim of this study is to evaluate
the financial impact of inputs for monitoring capillary blood glucose in relation to
medicinal products for treatment of diabetes mellitus in the state of Minas Gerais
in 2011. METHODS: Survey distribution and financial cost through the computer-
ized management of pharmaceutical assistance (SIGAF) in thez State of Minas
Gerais in 2011 of oral antidiabetics (glibenclamide 5 mg andmetformin hydrochlo-
ride 850mg), human insulinNPHand regular human insulin and indicator strip that
measures the glucose.RESULTS:The costs for regular andNPH Insulin in 2011were
U$8.320.793,31, with oral antidiabetic agents was U$2.032.284,77, as with reagent
strips for monitoring blood glucose level was U$6.978.321,99.The total spending on
drugs for the treatment of diabetesmellituswasU$10.353.078,08. It is observed that
the cost of test strips correspond to approximately 67.5% of this value.
CONCLUSIONS: These results demonstrate that the costs of inputs for monitoring
of blood glucose have a significant financial impact on the State diabetes program.
Moreover, they suggest the need for research regarding the reasonableness of the
use of these inputs by patients. Education strategies, such as the pharmaceutical
guidance for patients who perform self-monitoring blood glucose levels, aid in the
proper use of these inputs and can avoid any waste.
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OBJECTIVES: To assess the cost of various market share scenarios of leading re-
combinant human growth hormone (rhGH) pens to a commercial health plan,
taking into consideration drug and wastage costs due to device design.METHODS:
A budget impact model (BIM) was developed to determine the costs of rhGH prod-
ucts. Key model inputs included plan size, number of pediatric and adult patients,
mean [SD] weight, product dosing increments and annual wastage due to pen
devices having varying dosing increments. The BIM included storage and reconsti-
tution wastage as an option. Pediatric (n900) and adult (n100) patient weights
were assumed to be normally distributed with mean (SD) 30.25 (4.00) and 75.00
(2.00) kg. Assumed base case dosages were 0.03 mg/kg daily for pediatric patients;
brand-specific based on product package inserts for adult patients. Market share
was indexed at Year 1 (2011) and presented with 10%, 15% and 20% shifts to Nor-
ditropin from Genotropin, Humatrope, and Nutropin. Costs were based onWAC in
US dollars. RESULTS: Costs per patient per year (PPPY) were higher for Genotropin,
Humatrope and Nutropin vs. Norditropin ranging from approximately $23.1K to
$24.6K in pediatrics and $8.1 K to $9.2K in adults. Norditropin was associated with
the lowest annual milligrams of wastage (9.1 mg pediatric/ 8.5 mg adult, including
wastage due to storage and reconstitution) across all pen dosages, followed by
Nutropin (20.7 mg/ 19.9 mg), Humatrope (20.7 mg/20.2 mg) and Genotropin (30.6
mg/ 30.3 mg). Norditropin remained the least costly per year when: dosing from
package inserts was used, adult dosing was fixed, and when storage and reconsti-
tutionwastage was not included. CONCLUSIONS:Due to differences in cost permg
and wastage associated with design among the leading GH brands on the market,
use of Norditropin pens may result in cost savings.
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OBJECTIVES: Central precocious puberty (CPP) is generally treated with gonadotro-
pin releasing hormone (GnRH) agonists. The objective was to compare the costs of
first year treatment of monthly leuprolide acetate injections and once-a-year his-
trelin acetate implants. METHODS: Two retrospective cohort studies were con-
ducted using datasets derived from the Thomas Reuter’s MarketScan©Multi-State
Medicaid Database (2003-2007) and the MarketScan© Commercial Database (2005-
2009). Inclusion criteria were 2 claims with target diagnoses occurring 30 or more
days apart, enrollment for 3 months before first treatment, and continuous en-
rollment for 12 months after first treatment. A probabilistic patient flow model
was developed using estimates for treatment patterns and costs for products, office
visits, and monitoring therapy. RESULTS: A total of 4802 Medicaid and 7391 Com-
mercial beneficiaries age 12 years or younger were identified as diagnosed with
CPP. 323 Medicaid and 383 Commercial beneficiaries met the inclusion criteria and
were treated with leuprolide for 365 days or more. Medicaid and Commercial pa-
tients compliant with leuprolide (13 treatments/year) had an average of 14.8 and
14.0 treatments, respectively. Fifty-three percent of Medicaid and 54% of Commer-
cial patients were non-compliant and averaged 9.2 and 7.7 treatments, respec-
tively. Cost for treating 100 patients were simulated using existing levels of non-
compliance and an assumption that all patients should be compliant. Based on
current levels of non-compliance, costs for histrelin implants were 1.9% lower in
Medicaid and 6.5% higher in Commercial plans–however, when based on full com-
pliance, costs for histrelin implants were 12.9% lower in Medicaid and 12.1% lower
in Commercial plans. CONCLUSIONS:With current levels of non-compliance with
GnRH agonists, costs for CPP treatment is similar in Medicaid and slightly less
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